Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

d on the results of this study, Pharmasset and Roche plan to initiate a 28-day study of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1. Patient recruitment for this combination study is expected to begin in late September 2007. The purpose of this study is a preliminary evaluation of the safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy with the current standard of care consisting of Pegasys plus Copegus. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

In addition, a late breaker abstract for the Phase 1 multiple ascending dose study has been accepted as a presentation at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA from November 2-6, 2007. In accordance with the conference press embargo guidelines, no additional data will be available for this study until the scientific abstracts are published by AASLD on October 1, 2007.

Dr. Rajender Reddy, Professor of Medicine and Surgery in the Division of Gastroenterology at the University of Pennsylvania and a clinical investigator in the R7128 multiple ascending dose study, stated "The R7128 results are exciting based on the combination of potency, safety and tolerability. There were no major organ or other acute toxicities observed during the 14-day dosing period, which is encouraging for future studies with longer exposures to R7128 in combination with the standard of care. Leading clinicians believe that HCV therapy will evolve to include direct-acting antiviral drug combinations, and nucleoside polymerase inhibitors such as R7128 could improve sustained virologic response (SVR) rates for the treatment of chronic HCV."

"R7128 has demonstrated
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... June 1 DURECT Corporation (Nasdaq: DRRX ) announced today that ... the Jefferies Global Life Sciences Conference on Thursday, June 10 at ... Hotel in New York .   , ...   http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) , , , ...
... , June 1 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Officer, will present at the Jefferies 2010 Global Life Sciences Conference on ... the Grand Hyatt Hotel in New York, NY . , ... A live webcast of the presentation may be accessed ...
Cached Medicine Technology:DURECT to Present at the Jefferies Global Life Sciences Conference 2
(Date:7/9/2014)... winning is one of the key determinants that makes organized ... mental bonuses ranked near the bottom of 81 determinants of ... fun factors, according to a new study. Despite the common ... the "fun" factor, very little research had been done to ... now. , The results of this study might help researchers ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... research into the metabolism of stromal support cells and ... of these cell types in the development of diseases ... conditions and cancer. That was the conclusion of a ... in the leading journal Nature . , Prof. ... wake-up call. The metabolism of cancer cells has been ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
(Date:7/9/2014)... more than watching World Cup highlights, Brian Williams refreshing ... in unfortunate positions on railings. A University of Colorado ... Journal shows that YouTube also allows researchers, journals, ... on topics of skin cancer and prevention. , "No ... future of how we communicate around the world," says ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... by Dr. Agarwal Hospital:, An eye surgeon / scientist ... wide had thought we were 10 years away from,making DNA, ... the making of DNA and used it on her patients ... attributes the Science of Sri Vidya to this,phenomenal discovery. A ...
... fossil hunter and anatomy professor Kenneth Rose, Ph.D. was displaying ... seminar at the Johns Hopkins University School of Medicine when ... , That unanticipated eureka moment has led researchers at the ... rabbits. The fossil evidence in hand, found in west-central India, ...
... an estimated 10 to 13 percent of the American diet. ... in 2007 was $70.5 billion, with estimates for 2008 rising ... into the United States of imported food and food-related products ... which include ports, border crossings, and postal facilities. ...
... Plans for Growth, LAS VEGAS, March 19 ... members of its executive team presented,at the annual Citi ... on Wednesday, March 19, 2008., In addressing the ... and CEO Stephen Hughes recounted the accomplishments of,2007 and ...
... increase risk and may be early indication, study ... A combination of cholesterol-associated gene variants can increase ... sudden cardiac death, Massachusetts General Hospital researchers report. ... for these gene variants in order to identify ...
... than with freshly stored units, study finds , , ... get transfusions of blood that has been stored for ... get newer blood, a new study shows. , In-hospital ... were higher for those getting older blood, conclude physicians ...
Cached Medicine News:Health News:Science of Sri Vidya Benefits DNA Genesis, Says Dr. Sunita Rana Agarwal 2Health News:Good luck indeed: 53 million-year-old rabbit's foot bones found 2Health News:Smart Balance Presented at Citi Small/Midcap Conference 2Health News:Gene Variants Can Predict Threat of Heart Disease 2Health News:Transfusions of 'Older' Blood Don't Work as Well 2Health News:Transfusions of 'Older' Blood Don't Work as Well 3
Straight shafts with fine pierse type tips. Flat open serrated handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Jaws with fine teeth. Serrated handle with polished finish. Jaws: Wide, 4.5 mm. With thumb catch lock....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Medicine Products: